Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37


Therapeutic potential of a dual mTORC1/2 inhibitor for the prevention of posterior capsule opacification: An in vitro study.

Feng H, Yang Z, Bai X, Yang M, Fang Y, Zhang X, Guo Q, Ning H.

Int J Mol Med. 2018 Apr;41(4):2099-2107. doi: 10.3892/ijmm.2018.3398. Epub 2018 Jan 18.


Metformin and Cancer Treatment.

Di Mari A, Bordonaro S, Rametta Giuliano S, Romano F, Lanteri E, Tralongo P.

World J Oncol. 2015 Feb;6(1):316-317. doi: 10.14740/wjon868w. Epub 2015 Feb 14. No abstract available.


Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic.

Shah F, Logsdon D, Messmann RA, Fehrenbacher JC, Fishel ML, Kelley MR.

NPJ Precis Oncol. 2017;1. pii: 19. doi: 10.1038/s41698-017-0023-0. Epub 2017 Jun 8.


Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer.

Browne AJ, Kubasch ML, Göbel A, Hadji P, Chen D, Rauner M, Stölzel F, Hofbauer LC, Rachner TD.

Breast Cancer Res. 2017 Aug 9;19(1):92. doi: 10.1186/s13058-017-0885-7.


Emerging use of everolimus in the treatment of neuroendocrine tumors.

Gajate P, Martínez-Sáez O, Alonso-Gordoa T, Grande E.

Cancer Manag Res. 2017 Jun 20;9:215-224. doi: 10.2147/CMAR.S113382. eCollection 2017. Review.


Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.

Shimazu K, Tada Y, Morinaga T, Shingyoji M, Sekine I, Shimada H, Hiroshima K, Namiki T, Tatsumi K, Tagawa M.

BMC Cancer. 2017 May 2;17(1):309. doi: 10.1186/s12885-017-3300-y.


Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Teng CF, Wu HC, Shyu WC, Jeng LB, Su IJ.

Cell Transplant. 2017 Mar 13;26(3):429-438. doi: 10.3727/096368916X694382. Epub 2017 Feb 14. Review.


Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis.

Lu M, Zessin AS, Glover W, Hsu DS.

PLoS One. 2017 Jan 6;12(1):e0169439. doi: 10.1371/journal.pone.0169439. eCollection 2017.


Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.

Freitag H, Christen F, Lewens F, Grass I, Briest F, Iwaszkiewicz S, Siegmund B, Grabowski P.

Neuroendocrinology. 2017;105(1):90-104. doi: 10.1159/000448843. Epub 2016 Aug 12.


Adaptations to chronic rapamycin in mice.

Dodds SG, Livi CB, Parihar M, Hsu HK, Benavides AD, Morris J, Javors M, Strong R, Christy B, Hasty P, Sharp ZD.

Pathobiol Aging Age Relat Dis. 2016 May 27;6:31688. doi: 10.3402/pba.v6.31688. eCollection 2016.


The Enigma of Rapamycin Dosage.

Mukhopadhyay S, Frias MA, Chatterjee A, Yellen P, Foster DA.

Mol Cancer Ther. 2016 Mar;15(3):347-53. doi: 10.1158/1535-7163.MCT-15-0720. Epub 2016 Feb 25. Review.


Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve.

Koukourakis MI, Mitrakas AG, Giatromanolaki A.

Br J Cancer. 2016 Mar 1;114(5):485-96. doi: 10.1038/bjc.2016.19. Epub 2016 Feb 18. Review.


Effects of everolimus on a rat model of cerulein-induced experimental acute pancreatitis.

Özkardeş AB, Bozkurt B, Dumlu EG, Tokaç M, Yazgan AK, Ergin M, Erel Ö, Kılıç M.

Ulus Cerrahi Derg. 2015 Dec 1;31(4):185-91. doi: 10.5152/UCD.2015.3170. eCollection 2015.


Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.

Sun JD, Ahluwalia D, Liu Q, Li W, Wang Y, Meng F, Bhupathi D, Matteucci MD, Hart CP.

Am J Cancer Res. 2015 Jun 15;5(7):2139-55. eCollection 2015.


A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.

McRee AJ, Davies JM, Sanoff HG, Goldberg RM, Bernard S, Dees EC, Keller K, Ivanova A, O'Neil BH.

Cancer Chemother Pharmacol. 2014 Jul;74(1):117-23. doi: 10.1007/s00280-014-2474-0. Epub 2014 May 13.


Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.

Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, Martinez P, Phillimore B, Begum S, Rabinowitz A, Spencer-Dene B, Gulati S, Bates PA, Stamp G, Pickering L, Gore M, Nicol DL, Hazell S, Futreal PA, Stewart A, Swanton C.

Nat Genet. 2014 Mar;46(3):225-233. doi: 10.1038/ng.2891. Epub 2014 Feb 2.


Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis.

Yamanaka K, Petrulionis M, Lin S, Gao C, Galli U, Richter S, Winkler S, Houben P, Schultze D, Hatano E, Schemmer P.

Cancer Med. 2013 Dec;2(6):862-71. doi: 10.1002/cam4.150. Epub 2013 Oct 22. Review.


Oxyphenisatin acetate (NSC 59687) triggers a cell starvation response leading to autophagy, mitochondrial dysfunction, and autocrine TNFα-mediated apoptosis.

Morrison BL, Mullendore ME, Stockwin LH, Borgel S, Hollingshead MG, Newton DL.

Cancer Med. 2013 Oct;2(5):687-700. doi: 10.1002/cam4.107. Epub 2013 Jul 23.


AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines.

Leal P, Garcia P, Sandoval A, Buchegger K, Weber H, Tapia O, Roa JC.

Onco Targets Ther. 2013 Oct 3;6:1373-84. doi: 10.2147/OTT.S46897. eCollection 2013.

Supplemental Content

Support Center